AD
Avatrombopag(CAS: 570406-98-3)
CAS Number
Related Products
![4-(2H-Tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]benzamide](https://static.chemtradehub.com/structs/132/132640-22-3-f1d9.webp)
![3-(2,2-Dimethylpropyl)-5-[4-(4-fluorophenyl)-2-(2-methyl-2-propanyl)-1H-imidazol-5-yl]-3H-imidazo[4,5-b]pyridin-2-amine methanesulfonate (1:2)](https://static.chemtradehub.com/structs/862/862507-23-1-1cf2.webp)
![2-[4-[1-(4,4-Dimethyl-5H-Oxazol-2-Yl)-1-Methyl-Ethyl]Phenyl]Ethanol](https://static.chemtradehub.com/structs/361/361382-26-5-3f7d.webp)
![5-[(3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-N-(6-{[3-(2-pyridinyldisulfanyl)propanoyl]amino}hexyl)pentanamide](https://static.chemtradehub.com/structs/129/129179-83-5-e663.webp)
Other Suppliers for Avatrombopag
Basic Information
Molecular Formula
C29H34Cl2N6O3S2
Molecular Weight
649.67 g/mol
Physical Properties
Density
1.440
Chemical Identifiers
SMILES
C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
InChIKey
OFZJKCQENFPZBH-UHFFFAOYSA-N
Database References
MDL Number
MFCD18633249
FAQ
Avatrombopag (CAS: 570406-98-3) is subject to various regulatory guidelines including the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) in the European Union, and the U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) requirements for pharmaceuticals. It is essential to comply with these regulations for manufacturing, distribution, and usage.
Avatrombopag (CAS: 570406-98-3) has several analogs and structural isomers that can serve as alternatives in synthesis. Common alternatives include TPO agonists with similar mechanisms of action, such as eltrombopag and crizotinib, which can be used as substitutes depending on the specific requirements of the synthesis.
The market for Avatrombopag (CAS: 570406-98-3) is driven by growing demand in the treatment of thrombocytopenia. Research trends focus on its efficacy and safety in various clinical settings, including its use in hematological disorders and post-surgical conditions. Market trends indicate increasing interest in this TPO agonist as a therapeutic option.
Waste containing Avatrombopag (CAS: 570406-98-3) should be collected in appropriate containers and handled according to local waste disposal regulations. Incineration or professional waste disposal services are recommended to ensure environmental safety. Proper labeling and documentation of waste disposal processes are also critical to comply with environmental protection standards.
Safety Notice
Please verify product specifications and safety data before use. Contact the supplier for detailed safety information.
Always follow proper handling procedures